Serial Number
86374553
Owner
CureVac GmbHAttorney
Jennifer FraserFirst Use Date
Nov 11, 2014
Filing Date
Aug 22, 2014
RNAOPTIMIZER Trademark
Serial Number: 86374553 • Registration: 5271548
Trademark Classes
Class 1 - Chemicals
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Class 5 - Pharmaceuticals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Class 42 - Computer & Scientific
Scientific and technological services; industrial analysis and research services
Class 44 - Medical Services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Owner Contact Info
Legal Representation
Trademark Details
Filing Date
August 22, 2014
Registration Date
August 22, 2017
First Use Anywhere
November 11, 2014
First Use in Commerce
November 11, 2014
Published for Opposition
March 22, 2016
Cancellation Date
March 8, 2024
Goods & Services
CHEMICAL PREPARATIONS FOR PHARMACEUTICAL OR MEDICAL PURPOSES, NAMELY, FOR THE TREATMENT OF NEUROLOGICAL, NEUROMUSCULAR, NEURODEGENERATIVE AND CARDIOVASCULAR DISEASES, FOR THE TREATMENT OF INFECTIOUS DISEASES, AUTOIMMUNE DISEASES AND TUMOURS, FOR TREATMENT OF METABOLIC DISEASES AND FOR TREATMENT OF HERITABLE GENETIC DISEASES OR FOR THERAPIES REPLACING PROTEINS OR ENZYMES; PHARMACEUTICAL AND VETERNARY MEDICAL PREPARATIONS FOR THE TREATMENT OF NEUROLOGICAL, NEUROMUSCULAR, NEURODEGENERATIVE AND CARDIOVASCULAR DISEASES, FOR THE TREATMENT OF INFECTIOUS DISEASES, AUTOIMMUNE DISEASES AND TUMOURS, FOR TREATMENT OF METABOLIC DISEASES AND FOR TREATMENT OF HERITABLE GENETIC DISEASES OR FOR THERAPIES REPLACING PROTEINS OR ENZYMES; IMMUNOSTIMULATORY COMPOSITIONS; VACCINES, ADJUVANT IMMUNOSTIMULANTS; PHARMACEUTICALS AND MEDICAMENTS BASED ON/CONTAINING/PREPARED FROM BIOLOGICAL MACROMOLECULES FOR THE TREATMENT OF NEUROLOGICAL, NEUROMUSCULAR, NEURODEGENERATIVE AND CARDIOVASCULAR DISEASES, FOR THE TREATMENT OF INFECTIOUS DISEASES, AUTOIMMUNE DISEASES AND TUMOURS, FOR TREATMENT OF METABOLIC DISEASES AND FOR TREATMENT OF HERITABLE GENETIC DISEASES OR FOR THERAPIES REPLACING PROTEINS OR ENZYMES; GENE THERAPY PRODUCTS, NAMELY, NUCLEIC ACID MACROMOLECULES FOR IN VIVO EXPRESSION; FOOD SUPPLEMENTS FOR MEDICAL USE, ALL OF THE FOREGOING BEINGS GOODS WHICH TARGET OR WORK WITH RNA
CHEMICAL REAGENTS AND BIOMOLECULES, IN PARTICULAR BIOLOGICAL MACROMOLECULES FOR INDUSTRY AND SCIENCE, REAGENTS FOR RESEARCH PURPOSES, ALL OF THE FOREGOING BEING GOODS WHICH TARGET OR WORK WITH RNA
MEDICAL AND VETERINARY SERVICES, IN PARTICULAR FOR THERAPEUTICAL AND PROPHYLACTIC TREATMENT OF TUMOR DISEASES, INFECTIOUS DISEASES, AUTOIMMUNE DISEASES AND ALLERGIES, FOR THE TREATMENT OF HEREDITARY DISORDERS AND FOR PROTEIN OR ENZYME SUPPLEMENT THERAPY, FOR THE TREATMENT OF NEUROLOGICAL, NEUROMUSCULAR, NEURODEGENERATIVE AND CARDIOVASCULAR DISORDERS AND FOR THE TREATMENT OF ENDOCRINOLOGICAL DISORDERS
SCIENTIFIC AND TECHNOLOGICAL SERVICES AND RESEARCH SERVICES, IN PARTICULAR FOR IDENTIFYING AND CHARACTERIZING BIOLOGICAL MACROMOLECULES
